A late-stage study testing Bavencio (avelumab) has failed to meet its primary endpoints in patients with certain forms of ovarian cancer.
avelumab
-
November 29, 2018
A late-stage study testing Bavencio (avelumab) has failed to meet its primary endpoints in patients with certain forms of ovarian cancer.